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Abstract 
Background: A novel obesity classification method has been proposed using body mass index (BMI) and waist–
height ratio (WHtR) together. However, the utility of this approach is unclear. In this study we compare the metabolic 
profiles in subjects defined as overweight or obese by both measures. We examine a range of metabolic syndrome 
features, pro-inflammatory cytokines, acute-phase response proteins, coagulation factors and white blood cell counts 
to determine whether a combination of both indices more accurately identifies individuals at increased obesity-
related cardiometabolic risk.
Methods: This was a cross-sectional study involving a random sample of 1856 men and women aged 46–73 years. 
Metabolic and anthropometric profiles were assessed. Linear and logistic regression analyses were used to compare 
lipid, lipoprotein, blood pressure, glycaemic and inflammatory biomarker levels between BMI and WHtR tertiles. Mul-
tinomial logistic regression was performed to determine cardiometabolic risk feature associations with BMI and WHtR 
groupings. Receiver operating characteristic curve analysis was used to evaluate index discriminatory ability.
Results: The combination of BMI and WHtR tertiles identified consistent metabolic variable differences relative to 
those characterised on the basis of one index. Similarly, odds ratios of having cardiometabolic risk features were 
noticeably increased in subjects classified as overweight or obese by both measures when compared to study partici-
pants categorised by either BMI or WHtR separately. Significant discriminatory improvement was observed for detect-
ing individual cardiometabolic risk features and adverse biomarker levels. In a fully adjusted model, only individuals 
within the highest tertile for both indices displayed a significant and positive association with pre-diabetes, OR: 3.4 
(95 % CI: 1.9, 6.0), P < 0.001.
Conclusions: These data provide evidence that the use of BMI and WHtR together may improve body fat classifica-
tion. Risk stratification using a composite index may provide a more accurate method for identifying high and low-risk 
subjects.
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Background
Excess body fat has been shown to be associated with 
dyslipidaemia, hypertension, insulin resistance, chronic 
low-grade inflammation and the development of meta-
bolic syndrome (MetS), type 2 diabetes and cardiovas-
cular complications [1–4]. Numerous studies have also 
demonstrated a high mortality rate in subjects with a 
body mass index (BMI) ≥30  kg/m2 [5]. But because it 
is a weight-for-height measure, BMI is unable to distin-
guish between fat and lean mass and elevated BMI may 
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not always indicate increased adiposity or predict cardio-
metabolic events [6, 7].
Evidence suggests that central obesity is a more impor-
tant metabolic risk factor and waist circumference (WC) 
measurement has been recommended as a method for 
central obesity assessment [8, 9]. However, as WC diag-
nostic thresholds are different for men and women, and 
may vary between ethnic groups [10], the practical utility 
of WC measurement has been questioned [11].
The waist–height ratio (WHtR) (WC divided by height) 
has been advocated as an alternative surrogate measure 
of central obesity [12]. As a ratio, this index may circum-
vent problematic issues relating to gender or population-
specific risk cut-points [13, 14]. But results from studies 
which have compared BMI and WHtR discriminatory 
abilities have been inconclusive, with some showing 
WHtR to be only marginally superior to BMI for predict-
ing cardiometabolic outcomes [15–17].
The prevalence of obesity has escalated in many world 
populations [18]. Thus, there is an increasing need to 
identify overweight and obese individuals at highest odds 
of developing cardiometabolic diseases. Recently, a new 
obesity classification method was proposed, utilising 
BMI in conjunction with WHtR [14]. Risk stratification 
using a composite index may provide a more effective 
method for identifying high and low-risk subjects. This 
could allow earlier diagnosis, thus attenuating metabolic 
complications and chronic morbidity development.
The aim of this study was to compare the metabolic 
profiles in subjects defined as overweight or obese, using 
BMI and WHtR, in a random sample of 1856 middle-
aged men and women. In particular, we examined a range 
of MetS features, pro-inflammatory cytokines, acute-
phase response proteins, coagulation factors and white 
blood cell (WBC) counts to determine whether a combi-
nation of BMI and WHtR more accurately identifies indi-
viduals at increased obesity-related cardiometabolic risk.
Methods
Study population
The Cork and Kerry Diabetes and Heart Disease Study 
(Phase II) was a single centre, cross-sectional study con-
ducted between 2010 and 2011. A random sample was 
recruited from a large primary care centre in Mitchel-
stown, County Cork, Ireland. The Livinghealth Clinic 
serves a population of approximately 20,000, with a mix 
of urban and rural residents. Stratified sampling was 
employed to recruit equal numbers of men and women 
from all registered attending patients in the 46–73  year 
age group. In total, 3807 potential participants were 
selected from the practice list. Following the exclusion of 
duplicates, deaths, and subjects incapable of consenting 
or attending appointment, 3051 were invited to par-
ticipate in the study and of these, 2047 (49.2  % male) 
completed the questionnaire and physical examination 
components of the baseline assessment (response rate: 
67.1  %). Details regarding the study design, sampling 
procedures and methods of data collection have been 
reported previously [19].
Ethics committee approval conforming to the Declara-
tion of Helsinki was obtained from the Clinical Research 
Ethics Committee of University College Cork. A letter 
signed by the contact GP in the clinic was sent out to all 
selected participants with a reply slip indicating accept-
ance or refusal. All subjects gave signed informed con-
sent, including permission to use their data for research 
purposes.
Clinical and laboratory procedures
All study participants attended the clinic in the morn-
ing after an overnight fast and blood samples were taken 
on arrival. Data on age, gender, morbidity, prescription 
(Rx) medication use and smoking and alcohol behav-
iours were gathered through a self-completed General 
Health Questionnaire (GHQ). Physical activity levels 
were assessed using the validated International Physical 
Activity Questionnaire (IPAQ) [20]. Three independent 
measurements of systolic and diastolic blood pressure 
(BP) were obtained with the subject in a seated position 
using an Omron M7 digital sphygmomanometer (Omron 
Healthcare Co. Ltd., Japan). The mean of the second and 
third readings was considered to be a subject’s BP.
Triglyceride and high density lipoprotein choles-
terol (HDL-C) levels were measured by Cork University 
Hospital Biochemistry Laboratory on Olympus 5400 
biochemistry analysers with Olympus reagents using 
standardised procedures and fresh samples (Olympus 
Diagnostica GmbH, Hamburg, Germany). Glucose con-
centrations were determined using a glucose hexokinase 
assay (Olympus Life and Material Science Europa Ltd., 
Lismeehan, Co. Clare, Ireland) and glycated haemoglo-
bin A1c (HbA1c) levels were measured in the haematology 
laboratory on an automated high-pressure liquid chro-
matography instrument Tosoh G7 [Tosoh HLC-723 (G7), 
Tosoh Europe N.V, Tessenderlo, Belgium]. Serum insulin, 
c-reactive protein (CRP), tumour necrosis factor alpha 
(TNF-α), interleukin 6 (IL-6), adiponectin, leptin, resis-
tin and plasminogen activator inhibitor-1 (PAI-1) were 
assessed using a biochip array system (Evidence Investi-
gator; Randox Laboratories, UK). Complement compo-
nent 3 (C3) was measured by immunoturbidimetric assay 
(RX Daytona; Randox Laboratories). White blood cell 
counts were determined by flow cytometry technology as 
part of a full blood count.
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Classification of biochemical and blood pressure 
measurements
Patients with type 2 diabetes indicated by either 
HbA1c levels ≥6.5  % (≥48  mmol/mol) or FPG levels 
≥7.0  mmol/l, a self-reported physician diagnosis, Rx 
diabetes medication use, or those who were on insu-
lin therapy, were excluded (N  =  184). Lipid, lipopro-
tein and BP measurements were classified according to 
National Cholesterol Education Program Adult Treat-
ment Panel III guidelines [21]. Abnormal metabolic 
risks were defined as high triglycerides ≥1.7 mmol/l and 
low HDL-C (<1.03  mmol/l in males or <1.29  mmol/l in 
females). Dyslipidaemia was determined according to 
both high triglyceride and low HDL-C levels. High BP 
was classified as systolic BP ≥130 mmHg and/or diastolic 
BP ≥85 mmHg or Rx anti-hypertensive medication use. 
The Homeostasis Model Assessment of Insulin Resist-
ance (HOMA-IR) [22] was derived from fasting glucose 
and insulin concentrations as [(fasting plasma glucose x 
fasting serum insulin)/22.5] and insulin resistance was 
defined as a level equal to or above the 75th percentile 
in the study sample. Having three or more MetS risk 
features (≥3 metabolic features) was characterised as 
any combination of the following: high triglycerides, 
low HDL-C levels, high BP and insulin resistance. Sub-
jects were classified as having pre-diabetes if they had 
both elevated HbA1c levels ≥5.7  % (≥39  mmol/mol) 
and impaired fasting plasma glucose levels ≥5.6 mmol/l 
[23]. As internationally recognised risk cut-points for 
the examined biomarkers have not been established, we 
classified inflammation and raised immune activation 
as a level equal to or above the 75th percentile for each 
biomarker (C3, CRP, IL-6, TNF-α, leptin, resistin, PAI-1 
and WBC) with the exception of adiponectin (equal to or 
below the 25th percentile).
Anthropometric variables
The weight and height of each participant were measured 
to the nearest 0.1  kg and 0.1  cm respectively. Portable 
electronic Tanita WB-100MA weighing scales (Tanita 
Corporation, IL, USA) were placed on a firm, flat surface 
and were calibrated weekly to ensure accuracy. Height 
was measured using a portable Seca Leicester height/
length stadiometer (Seca, Birmingham, UK) and BMI 
was calculated as weight divided by the square of height. 
Waist circumference was measured immediately below 
the lowest rib at the mid-axillary line on bare skin. Sub-
jects were instructed to breathe in, and then out, and to 
hold their breath while measurement was made to the 
nearest 0.1  cm using a Seca 200 measuring tape. The 
WHtR was calculated as WC divided by height. Two 
independent readings were taken for WC and the mean 
of the two was used in analysis.
Both BMI and WHtR were divided into equal tertiles. 
Subjects were categorised on the basis of their BMI or 
WHtR percentiles as normal weight (<33  %), overweight 
(33–66  %) and obese (>66  %). In our sample these cut-
points corresponded to <26.2, 26.2–29.7, >29.7 for BMI 
and <0.52, 0.52–0.58, >0.58 for WHtR. The BMI and 
WHtR groups were combined to form a 5-category vari-
able: (1) normal weight by both, (2) overweight by either, 
(3) overweight by both, (4) obese by either and (5) obese 
by both. Overweight subjects classified as obese by 
either index were assigned to the higher category. Seven 
subjects had missing anthropometric values and were 
excluded from statistical analysis.
Lifestyle data
Lifestyle variables utilised from the IPAQ [20] and GHQ 
included physical activity level, smoking status and alco-
hol use. Self-reported physical activity within the previ-
ous 6 months was collapsed into two categories: high or 
moderate (N = 1324) and no physical exercise (N = 312). 
Subjects were considered to be current smokers if they 
smoked cigarettes during the recruitment phase of the 
study (N  =  257). Alcohol use was assessed by asking 
study participants how often they consumed alcohol on 
a monthly or weekly basis, and was dichotomised as fol-
lows: ‘never or less than once a month’ and ‘2–4 times 
monthly’—occasional drinker (N =  1165), and ‘twice or 
more weekly’—regular drinker (N = 614).
Statistical analysis
Data analysis was conducted using IBM SPSS Statistics 
Version 20 (IBM Corp., Armonk, NY, USA) and Stata 
SE Version 13 (Stata Corporation, College Station, TX, 
USA) for Windows. Descriptive characteristics were 
examined according to normal weight, overweight and 
obese defined by BMI and WHtR tertiles. Dichotomous 
features are presented as percentages and continuous 
variables are shown as a mean (plus or minus one stand-
ard deviation) or a median and interquartile range for 
skewed data. Linear and logistic regression (adjusting for 
gender) were used to examine continuous and dichoto-
mous metabolic variable differences between overweight 
and obese categories. Skewed continuous data were log10 
transformed. Multinomial logistic regression was per-
formed to determine cardiometabolic risk feature asso-
ciations with each BMI and WHtR tertile combination. 
Subjects classified as normal weight by both indices were 
used as the reference category. All multinomial regres-
sion models were adjusted using age, gender, physical 
activity, smoking status and alcohol use as independent 
covariates.
The discriminatory ability of BMI, WHtR, and both 
BMI and WHtR used together, was assessed using 
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receiver operating characteristic curve (ROC) analysis. 
The area under the curve (AUC) provides a scale from 
0.5 to 1.0 (with 0.5 representing random chance and 1.0 
indicating perfect discrimination) by which to appraise 
the capacity of an obesity index to detect a positive 
result. Three separate analyses were performed. The first 
analysis assessed each anthropometric measure as a con-
tinuous variable. The second analysis explored cardio-
metabolic risk feature discrimination using index tertiles. 
A final analysis examined the 5-category BMI/WHtR 
combination variable used in previous regression models. 
Significant differences between AUC values were deter-
mined. For all analyses, a P value (two-tailed) of less than 
0.05 was considered to indicate statistical significance.
Results
Descriptive characteristics
The characteristics of the study population were sum-
marised according to BMI and WHtR tertiles (Table 1). A 
higher tertile level was related to an increased cardiomet-
abolic risk profile as defined by lipid/lipoprotein, BP, gly-
caemic indicator and biomarker levels, with obese groups 
showing the highest proportion of cardiometabolic risk 
factors. In general, cardiometabolic profiles were broadly 
similar across BMI and WHtR overweight and obese cat-
egories, with the percentage of subjects with dyslipidae-
mia, high BP, insulin resistance, ≥3 metabolic features 
and pre-diabetes showing little variation according to 
classification by either index.
Cardiometabolic profiles according to classification 
of normal weight, overweight and obese
The levels of agreement between normal weight, over-
weight and obese tertiles are shown in Fig. 1. Kappa sta-
tistics were similar for normal and obese classifications 
(Kappa: 0.66, SE: 0.02 for normal weight vs. Kappa: 0.68, 
SE: 0.02 for obese) with marginal overlap between sub-
jects defined as overweight (Kappa: 0.38, SE: 0.02). In 
both overweight and obese groups (Table  2), the com-
bination of BMI and WHtR tertiles identified consistent 
and significant metabolic variable differences relative 
to those characterised on the basis of one index. Sub-
jects that were classified as overweight or obese by both 
indices displayed higher mean BMI, WC and median 
triglyceride levels, reduced HDL-C and adiponectin 
concentrations, and a higher percentage had adverse 
biomarker levels, insulin resistance, metabolic feature 
clustering and pre-diabetes.
Associations between cardiometabolic risk features 
and BMI/WHtR combinations
Table 3 presents results from multinomial logistic regres-
sion models examining each BMI and WHtR tertile 
combination. A clear dose–response association was 
noted, with odds ratios of having cardiometabolic risk 
features being noticeably increased in subjects classi-
fied by both indices. In univariate analysis (not shown), 
odds ratios of having pre-diabetes were 0.6 (95 % CI: 0.3, 
1.5), 1.9 (95 % CI: 1.1, 3.4), 1.8 (95 % CI: 1.0, 3.3) and 4.1 
(95 % CI: 2.5, 6.7) for subjects categorised as overweight 
by either, overweight by both, obese by either and obese 
by both measures respectively. In a fully adjusted model, 
only patients within the highest BMI and WHtR tertile 
displayed a significant and positive association with pre-
diabetes defined by both HbA1c and fasting plasma glu-
cose levels, OR: 3.4 (95 % CI: 1.9, 6.0), P < 0.001.
Discrimination of cardiometabolic risk features
In ROC analysis (Table  4), when used as a continuous 
variable, significantly higher AUC values for WHtR were 
found to discriminate high triglycerides, ≥3 metabolic 
features, elevated C3 and WBC levels when compared 
to BMI. BMI displayed a significantly higher AUC for 
detecting increased leptin levels compared to WHtR. A 
combination of both measures displayed significantly 
higher discriminatory accuracy for high triglycerides, 
metabolic feature clustering, C3 and CRP compared 
to BMI, and for leptin compared to WHtR. Significant 
improvement for detecting insulin resistance and high 
WBC levels were noted compared to when either BMI or 
WHtR were used independently.
When indices were examined as tertiles, significant dif-
ferences between BMI and WHtR remained for discrimi-
nating high triglyceride, leptin and WBC concentrations. 
The BMI/WHtR 5-category variable was a significantly 
better discriminator of high triglycerides, low HDL-C, 
pre-diabetes, high C3, CRP, IL-6, TNF-α and WBC lev-
els compared to BMI, and of leptin compared to WHtR. 
Significantly higher AUC values for detecting insulin 
resistance and ≥3 metabolic features were also found 
compared to when either measure were used alone.
Discussion
The aim of this study was to determine whether risk 
stratification using BMI and WHtR together more accu-
rately identifies individuals at increased obesity-related 
cardiometabolic risk. Our findings indicate that both 
measures classify different subjects, particularly within 
the overweight range. These results also demonstrate 
that individuals defined as overweight or obese, by both 
BMI and WHtR, exhibit different cardiometabolic pro-
files compared to subjects categorised by either index 
separately. Participants identified by both measures dem-
onstrated stronger associations with individual cardio-
metabolic risk factors, metabolic feature clustering and 
displayed a more pro-inflammatory, pro-antherogenic 
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Table 1 Characteristics of the study population
Mean and ±standard deviation are shown for continuous variables. Age, triglycerides, glucose, insulin, HOMA-IR, HbA1c, CRP, IL-6, TNF-α, adiponectin, leptin and 
resistin are shown as a median (interquartile range). % (in brackets) for dichotomous variables will vary as some variables have missing values
a Triglycerides ≥1.7
b HDL-C <1.03 (males) or HDL-C <1.29 (females)
c Systolic BP ≥130 and/or diastolic BP ≥85 or use of Rx anti-hypertensives
d HOMA-IR ≥2.96
e Both HbA1c levels ≥5.7 % and fasting plasma glucose levels ≥5.6
f Threshold: C3 ≥148; CRP ≥2.25; IL-6 ≥2.72; TNF-α ≥7.2; adiponectin ≤3.1; leptin ≥3.07; resistin ≥6.6; PAI-1 ≥33.66; WBC ≥6.6
Feature Normal weight Overweight Obese
BMI (N = 619) WHtR (N = 619) BMI (N = 618) WHtR (N = 618) BMI (N = 619) WHtR (N = 619)
Male 212 (34.2) 145 (23.4) 346 (56.0) 349 (56.5) 327 (52.8) 391 (63.2)
Age 58 (54, 63) 57 (54, 62) 59 (54, 63) 59 (54, 64) 60 (55, 64) 60 (55, 64)
Weight (kg) 64.6 ± 8.5 65.6 ± 9.4 78.3 ± 9.1 78.6 ± 10.2 92.5 ± 12.6 91.2 ± 13.5
BMI (kg/m2) 23.7 ± 1.8 24.3 ± 2.5 27.9 ± 1.0 27.9 ± 2.2 33.3 ± 3.5 32.7 ± 4.0
WC (cm) 79.7 ± 8.9 77.7 ± 7.2 91.8 ± 8.0 92.2 ± 5.8 102.7 ± 10.0 104.3 ± 8.4
WHtR 0.48 ± 0.04 0.47 ± 0.03 0.55 ± 0.04 0.55 ± 0.02 0.62 ± 0.05 0.62 ± 0.04
Triglycerides (mmol/l) 1.0 (0.8, 1.3) 1.0 (0.8, 1.3) 1.2 (0.9, 1.7) 1.2 (0.9, 1.7) 1.4 (1.0, 2.0) 1.5 (1.1, 2.0)
High triglyceridesa 67 (11.0) 49 (8.0) 147 (24.5) 152 (25.5) 195 (33.3) 208 (35.1)
HDL-C (mmol/l) 1.7 ± 0.4 1.7 ± 0.4 1.4 ± 0.3 1.4 ± 0.3 1.3 ± 0.3 1.3 ± 0.3
Low HDL-Cb 46 (7.6) 39 (6.4) 74 (12.2) 80 (13.2) 142 (23.8) 143 (24.0)
Dyslipidaemia 12 (2.0) 10 (1.6) 37 (6.1) 37 (6.1) 69 (11.5) 71 (11.9)
Systolic BP (mmHg) 124.9 ± 17.4 124.8 ± 17.2 129.5 ± 15.5 129.2 ± 15.5 133.0 ± 15.9 133.4 ± 16.0
Diastolic BP (mmHg) 77.2 ± 9.6 77.8 ± 9.6 80.7 ± 8.8 80.3 ± 9.4 82.5 ± 9.9 82.3 ± 9.5
High BPc 271 (43.8) 263 (42.5) 359 (58.2) 366 (59.3) 471 (76.3) 472 (76.5)
Glucose (mmol/l) 4.8 (4.5, 5.0) 4.7 (4.5, 5.0) 4.9 (4.6, 5.2) 4.9 (4.7, 5.2) 5.1 (4.7, 5.4) 5.1 (4.8, 5.5)
Insulin (µU/ml) 5.3 (3.8, 7.9) 5.3 (3.8, 7.9) 8.4 (5.7, 12.0) 8.3 (5.6, 12.2) 12.9 (8.2, 18.4) 12.9 (8.4, 18.4)
HOMA-IR 1.1 (0.8, 1.7) 1.1 (0.8, 1.7) 1.8 (1.2, 2.7) 1.8 (1.2, 2.7) 2.9 (1.8, 4.3) 2.9 (1.9, 4.3)
Insulin resistanced 31 (5.2) 29 (4.9) 121 (20.2) 122 (20.4) 293 (49.4) 294 (49.6)
≥3 metabolic features 16 (2.6) 13 (2.1) 63 (10.2) 59 (9.5) 163 (26.3) 170 (27.5)
HbA1c (%) 5.6 (5.4, 4.8) 5.6 (5.4, 5.8) 5.7 (5.5, 5.8) 5.7 (5.5, 5.9) 5.7 (5.5, 6.0) 5.7 (5.5, 6.0)
Pre-diabetese 27 (4.4) 26 (4.3) 49 (8.1) 41 (6.7) 86 (14.2) 95 (15.7)
C3 (mg/dl) 125.7 ± 22.9 125.2 ± 22.4 134.2 ± 22.7 135.2 ± 22.8 144.5 ± 22.9 144.0 ± 22.8
High C3f 79 (13.2) 77 (12.8) 133 (22.0) 137 (22.6) 239 (39.8) 237 (39.6)
CRP (ng/ml) 1.1 (0.8, 1.6) 1.1 (0.8, 1.6) 1.3 (1.0, 1.9) 1.3 (1.0, 2.0) 1.7 (1.2, 3.1) 1.8 (1.2, 3.0)
High CRPf 91 (15.1) 85 (14.1) 124 (20.5) 136 (22.4) 236 (39.4) 230 (38.5)
IL-6 (pg/ml) 1.4 (1.0, 2.3) 1.4 (1.0, 2.1) 1.6 (1.2, 2.5) 1.7 (1.2, 2.5) 2.1 (1.5, 3.3) 2.2 (1.5, 3.4)
High IL-6f 118 (19.5) 102 (16.9) 126 (20.9) 129 (21.3) 207 (34.5) 220 (36.8)
TNF-α (pg/ml) 5.6 (4.6, 6.9) 5.5 (4.5, 6.6) 5.9 (4.9, 7.2) 5.8 (4.9, 7.1) 6.3 (5.2, 7.5) 6.4 (5.3, 7.7)
High TNF-αf 117 (19.4) 110 (18.2) 153 (25.4) 140 (23.1) 181 (30.2) 201 (33.6)
Adiponectin (ng/ml) 6.6 (4.2, 9.8) 6.9 (4.7, 10.2) 4.6 (2.9, 6.9) 4.6 (2.9, 6.9) 4.1 (2.6, 6.3) 3.8 (2.5, 5.5)
Low adiponectinf 78 (12.9) 65 (10.8) 176 (29.1) 167 (27.6) 199 (33.2) 221 (36.9)
Leptin (ng/ml) 1.3 (0.6, 2.0) 1.4 (0.8, 2.1) 1.8 (1.0, 2.7) 1.8 (1.0, 2.8) 3.1 (1.9, 5.1) 2.7 (1.6, 4.7)
High leptinf 39 (6.5) 67 (11.1) 109 (18.0) 122 (20.1) 303 (50.5) 262 (43.7)
Resistin (ng/ml) 4.8 (3.9, 6.4) 4.9 (3.8, 6.4) 4.9 (3.7, 6.5) 4.9 (3.8, 6.6) 5.3 (4.0, 7.0) 5.2 (4.0, 6.7)
High resistinf 133 (22.0) 136 (22.5) 141 (23.3) 152 (25.1) 178 (29.7) 164 (27.4)
PAI-1 (ng/ml) 24.3 ± 10.3 24.0 ± 10.4 28.1 ± 13.6 27.5 ± 11.7 28.7 ± 12.0 29.7 ± 13.7
High PAI-1f 100 (16.6) 94 (15.6) 164 (27.2) 161 (26.6) 187 (31.2) 196 (32.8)
WBC (109/l) 5.7 ± 2.4 5.5 ± 1.6 5.8 ± 1.6 5.9 ± 2.3 6.1 ± 1.5 6.3 ± 1.5
High WBCf 125 (20.7) 103 (17.0) 149 (24.5) 153 (25.3) 177 (29.7) 195 (32.7)
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and insulin resistant profile. Use of both indices also sig-
nificantly improved discrimination of cardiometabolic 
risk features. These results suggest that joint use of BMI 
and WHtR may be clinically useful as a method to detect 
individuals at risk of cardiometabolic disorders.
Although it is straightforward to assess, and easy 
to calculate, limitations regarding the use of BMI as a 
sole method for adiposity appraisal have been widely 
acknowledged [7, 11]. Though frequently employed 
within epidemiological research and healthcare prac-
tice, BMI does not discriminate between fat and lean 
body mass, therefore persons of short stature or mus-
cular build may be misidentified [24]. Recent research 
has indicated that general obesity categorisation based 
on BMI might be inadequate [25]. Importantly, the find-
ing that approximately half of obese subjects are meta-
bolically healthy when classified using dual-energy X-ray 
absorptiometry-derived body fat percentage, compared 
to approximately one-third by BMI [26], signals that cau-
tion should be exercised with regard to how obesity is 
defined [24].
Compared with BMI, WC is thought to be more 
strongly correlated with visceral adipose tissue (VAT) 
which has been shown to be associated with increased 
risk of dyslipidaemia, hypertension and type 2 diabetes 
[9, 27, 28]. Though the exact mechanism of association 
between VAT and metabolic risk is still poorly under-
stood, research has implied that fatty acids released 
from VAT drain into the liver and skeletal muscle, caus-
ing metabolic dysfunction within these organs [29]. 
Adipokines secreted from VAT may also contribute to 
cardiometabolic disease through inflammation of vascu-
lar tissue [8, 30]. Although WC measurement has been 
recommended as a method for VAT and cardiometabolic 
risk assessment, controversy exists regarding its clinical 
efficacy. In particular, the need for gender and ethnic-
specific risk cut-points, and the fact that WC does not 
take whole body fat distribution into account, indicate 
constraints regarding its practical application and useful-
ness within a clinical setting [11].
The WHtR is potentially advantageous as it may not 
require conversion to gender or population-specific 
cut-offs or percentiles [13]. It has been previously sug-
gested that a WHtR ≥0.5 may serve as a useful bound-
ary for increased cardiometabolic risk, with a WHtR 
≥0.6 threshold indicating substantially increased risk 
[14]. Additionally, it has been shown that height has an 
inverse association with cardiovascular disease mortality 
and total mortality [31, 32], indicating that its use within 
an adiposity variable may be clinically important. In a 
recent meta-analysis of 31 prospective or cross-sectional 
studies, Ashwell et al. demonstrated WHtR to be a better 
discriminator of hypertension, metabolic syndrome, type 
2 diabetes and cardiovascular disease when compared to 
BMI [15]. Pooled results showed that WHtR improved 
discrimination of all outcomes by 3–4 %. However, other 
studies have suggested that differences in predictive abili-
ties are minimal, and have questioned the measurement 
of height in addition to WC [17].
The results from our research suggest that both BMI 
and WHtR provide important and independent informa-
tion, and that joint measurement may help refine body fat 
risk classification. Within our sample it was noted that 
participants who were categorised as overweight on the 
basis of one index also displayed an increased cardio-
metabolic risk profile. As a percentage of these individu-
als might be considered normal weight if either measure 
were used alone, these results indicate that use of both 
indices may provide a more sensitive method for detect-
ing patients at increased cardiometabolic risk. We also 
observed noticeably strong associations with cardio-
metabolic risk factors in subjects who were classified as 
overweight or obese by both BMI and WHtR together. 
This suggests that joint measurement may equally pro-
vide a more specific procedure for identifying high-risk 
subjects within overweight and obese categories. In par-
ticular, patients within the highest tertile for both indi-
ces were at a significantly higher risk compared to other 
obese subjects. In addition, a significant association with 
pre-diabetes was only observed within this tertile after 
a b c
Fig. 1 Overlap of normal weight, overweight and obese defined by BMI and WHtR. The figure shows Venn diagrams illustrating overlap of BMI and 
WHtR tertiles for (a) normal weight, (b) overweight and (c) obese
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Table 2 Cardiometabolic profiles according to classification of normal weight, overweight and obese defined by either 
BMI, WHtR or both
Mean and ±standard deviation are shown for continuous variables. Age, triglycerides, glucose, insulin, HOMA-IR, HbA1c, CRP, IL-6, TNF-α, adiponectin, leptin and 
resistin are shown as a median (interquartile range). % (in brackets) for dichotomous variables will vary as some variables have missing values
a P value for difference: overweight by either compared to overweight by both
b P value for difference: obese by either compared to obese by both
c x2 for difference
d Mann Whitney U for difference
e P value for difference adjusted for gender. Overweight subjects classified as obese by either index were assigned to the higher category











Malec 122 (25.5) 105 (39.9) 231 (63.6) <0.001 136 (51.5) 291 (59.8) 0.03
Aged 58 (54, 62) 58 (54, 65) 59 (54, 63) 0.885 59 (54, 64) 60 (55, 64) 0.15
Weight (kg)e 63.1 ± 8.1 71.9 ± 8.0 79.6 ± 9.2 <0.001 81.8 ± 9.5 94.6 ± 12.6 <0.001
BMI (kg/m2)e 23.3 ± 1.8 26.2 ± 1.5 27.9 ± 1.0 <0.001 29.7 ± 1.9 33.8 ± 3.6 <0.001
WC (cm)e 76.6 ± 7.2 85.7 ± 6.7 93.0 ± 5.7 <0.001 95.1 ± 7.2 105.7 ± 8.5 <0.001
WHtRe 0.46 ± 0.03 0.52 ± 0.03 0.55 ± 0.02 <0.001 0.57 ± 0.03 0.63 ± 0.05 <0.001
Triglycerides  
(mmol/l)e
0.9 (0.7, 1.2) 1.1 (0.8, 1.5) 1.3 (0.9, 1.7) 0.005 1.3 (1.0, 1.8) 1.5 (1.1, 2.0) 0.034
High triglyceridese 36 (7.6) 43 (16.7) 93 (26.6) 0.031 71 (27.7) 166 (35.8) 0.06
HDL-C (mmol/l)e 1.7 ± 0.4 1.6 ± 0.4 1.4 ± 0.3 <0.001 1.4 ± 0.3 1.3 ± 0.3 <0.001
Low HDL-Ce 31 (6.7) 23 (8.8) 46 (12.9) 0.038 39 (15.1) 123 (26.3) 0.001
Dyslipidaemiae 7 (1.5) 8 (3.1) 21 (5.9) 0.059 24 (9.3) 58 (12.3) 0.253
Systolic BP (mmHg)e 124.2 ± 17.5 126.4 ± 16.2 129.4 ± 14.7 0.027 132.5 ± 16.4 133.4 ± 15.8 0.52
Diastolic BP (mmHg)e 77.1 ± 9.6 78.8 ± 9.4 80.5 ± 8.8 0.003 82.2 ± 9.3 82.5 ± 9.8 0.61
High BPe 195 (40.7) 134 (51.0) 213 (58.8) 0.069 175 (66.3) 384 (79.2) <0.001
Glucose (mmol/l)e 4.7 (4.5, 5.0) 4.8 (4.6, 5.1) 4.9 (4.7, 5.3) 0.038 4.9 (4.7, 5.2) 5.1 (4.8, 5.5) <0.001
Insulin (µU/ml)e 5.1 (3.7, 7.5) 6.2 (4.3, 9.2) 8.8 (6.0, 12.1) <0.001 10.2 (6.8, 14.3) 14.0 (9.0, 20.2) <0.001
HOMA-IRe 1.1 (0.8, 1.6) 1.4 (0.9, 2.0) 2.0 (1.3, 2.7) <0.001 2.2 (1.5, 3.2) 3.2 (2.0, 4.6) <0.001
Insulin resistancee 20 (4.4) 20 (7.8) 72 (20.5) <0.001 79 (31.1) 254 (54.5) <0.001
≥3 metabolic  
featurese
8 (1.7) 13 (4.9) 35 (9.6) 0.024 39 (14.8) 147 (30.2) <0.001
HbA1c (%)
e 5.6 (5.4, 5.8) 5.7 (5.5, 5.9) 5.7 (5.4, 5.8) 0.54 5.7 (5.5, 5.8) 5.8 (5.6, 6.0) 0.002
Pre-diabetese 22 (4.7) 8 (3.1) 31 (8.7) 0.018 21 (8.1) 80 (16.8) 0.002
C3 (mg/dl)e 124.0 ± 23.1 130.2 ± 20.4 134.7 ± 23.0 <0.001 139.2 ± 23.2 145.7 ± 22.9 <0.001
High C3e 56 (12.1) 42 (16.2) 77 (21.8) 0.013 76 (29.1) 200 (42.6) <0.001
CRP (ng/ml)e 1.0 (0.8, 1.5) 1.3 (1.0, 2.0) 1.3 (1.0, 1.8) 0.976 1.5 (1.1, 2.5) 1.8 (1.2, 3.2) <0.001
High CRPe 60 (12.9) 52 (20.1) 67 (18.9) 0.891 78 (30.1) 194 (41.4) <0.001
IL-6 (pg/ml)e 1.3 (1.0, 2.1) 1.4 (1.1, 2.4) 1.7 (1.2, 2.4) 0.317 1.9 (1.3, 2.9) 2.3 (1.6, 3.5) 0.001
High IL-6e 82 (17.6) 49 (18.9) 70 (19.7) 0.99 73 (28.3) 177 (37.7) 0.01
TNF-α (pg/ml)e 5.5 (4.6, 6.7) 5.8 (4.6, 6.9) 5.9 (4.9, 7.2) 0.521 5.8 (5.0, 7.3) 6.4 (5.3, 7.0) 0.067
High TNF-αe 87 (18.7) 50 (19.4) 89 (25.1) 0.276 68 (26.4) 157 (33.4) 0.047
Adiponectin (ng/ml)e 7.0 (4.7, 10.3) 5.9 (3.8, 9.0) 4.2 (2.7, 6.3) <0.001 4.8 (2.9, 6.7) 3.8 (2.5, 5.5) 0.023
Low adiponectine 48 (10.3) 43 (16.6) 117 (33.0) 0.007 70 (27.0) 175 (37.2) 0.032
Leptin (ng/ml)e 1.3 (0.7, 2.0) 1.6 (1.0, 2.4) 1.7 (0.9, 2.7) 0.001 2.3 (1.3, 4.0) 3.2 (1.9, 5.2) <0.001
High leptine 30 (6.5) 39 (15.1) 56 (15.8) 0.009 87 (33.6) 239 (50.9) <0.001
Resistin (ng/ml)e 4.9 (3.8, 6.4) 4.8 (3.8, 6.7) 4.9 (3.7, 6.4) 0.946 4.9 (4.0, 6.8) 5.3 (4.0, 7.0) 0.274
High resistine 100 (21.5) 66 (25.5) 79 (22.3) 0.452 72 (27.9) 135 (28.7) 0.611
PAI-1 (ng/ml)e 23.8 ± 10.2 25.5 ± 10.9 28.1 ± 12.0 0.033 29.3 ± 15.6 29.2 ± 12.1 0.761
High PA1-1e 69 (14.8) 52 (20.2) 103 (29.0) 0.046 71 (27.5) 156 (33.2) 0.161
WBC (109/l)e 5.5 ± 1.7 5.8 ± 3.0 5.9 ± 1.6 0.92 6.1 ± 1.6 6.2 ± 1.4 0.345
High WBCe 84 (17.9) 56 (22.0) 88 (24.6) 0.832 74 (28.7) 149 (31.9) 0.418
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adjustment for other risk factors. This might imply that 
the relationship between obesity and diabetes is better 
indicated at this mode and level of adiposity.
Nevertheless, it was also noted that subjects classi-
fied by both indices were, on average, more overweight 
or obese, and thus would probably be identified if either 
BMI or WHtR were used alone. Additionally, discrimina-
tory improvements for detecting individual cardiometa-
bolic features were modest. However, cardiometabolic 
diseases are multifactorial, as it has been shown that sub-
jects with a combination of features are at higher risk of 
cardiometabolic events [33, 34]. Also, a degree of meas-
urement error is to be expected during any anthropo-
metric assessment. We have recently shown that using 
BMI and WHtR together significantly improves discrimi-
nation of type 2 diabetes [30]. Cut-points on the ROC 
demonstrated greater sensitivity and specificity than 
when either index were used independently. As the sum 
of risk factors may be greater than the individual parts 
for predicting cardiometabolic events, and as measure-
ment error may limit the minimal detectable difference 
in a cardiometabolic risk parameter [35], it could be that 
these findings are due to the greater measurement accu-
racy that joint BMI and WHtR assessment may provide.
Although it is hoped that public health programs 
may eventually reduce the prevalence of obesity-related 
metabolic disorders, current strategies to combat obe-
sity are failing as overweight and obesity rates continue 
to increase worldwide [18]. As a percentage of obese 
subjects are considered to be metabolically healthy [24], 
there is an increasing need for cheap and non-invasive 
methods to detect overweight and obese individuals at 
highest odds of developing cardiometabolic diseases. In 
previous research we have shown that assessing both bio-
electrical impedance-derived body fat percentage and 
BMI may help to discriminate individuals at greater car-
diometabolic risk than BMI alone [36]. Those identified 
using both tools had a more metabolically unhealthy pro-
file and were non-responsive to dietary changes. These 
findings suggest that stratification of obese individuals, 
based on their metabolic health phenotype, could be 
important in the early identification of those who should 
be prioritised for pharmacological and lifestyle interven-
tions [24]. Joint use of BMI and WHtR may provide a 
convenient and inexpensive means for risk stratification. 
Such a method might be useful in resource-poor settings 
where blood sampling is unavailable, or in populations 
without regular access to primary health services.
As far as we are aware, our study is the first to com-
prehensively examine the joint use of BMI and WHtR in 
a middle-aged European population. Strengths include a 
high participation rate, the use of questionnaires to assess 
Table 3 Odds ratios (95 % CI) of having cardiometabolic risk features according to classification of overweight and obese
a Multinomial logistic regression, reference category: normal weight by both BMI and WHtR. Overweight subjects classified as obese by either index were assigned to 
the higher category. All models adjusted for age, gender, physical activity, smoking and alcohol use
Feature Odds ratios (95 % CI)a
Overweight compared to normal weight Obese compared to normal weight
Either BMI  
or WHtR
P value Both BMI 
and WHtR
P value Either BMI  
or WHtR
P value Both BMI  
and WHtR
P value
High triglycerides 2.1 (1.3, 3.5) 0.003 3.5 (2.3, 5.4) <0.001 3.4 (2.1, 5.5) <0.001 5.6 (3.7, 8.6) <0.001
Low HDL-C 1.4 (0.8, 2.5) 0.3 2.1 (1.3, 3.7) 0.005 2.2 (1.2, 3.8) 0.008 5.8 (3.6, 9.2) <0.001
Dyslipidaemia 1.8 (0.6, 5.3) 0.263 3.8 (1.5, 9.3) 0.004 4.6 (1.9, 11.6) 0.001 8.6 (3.7, 19.6) <0.001
High BP 1.5 (1.1, 2.1) 0.02 2.1 (1.5, 2.8) <0.001 3.0 (2.1, 4.2) <0.001 5.7 (4.1, 7.9) <0.001
Insulin resistance 1.8 (0.9, 3.7) 0.083 5.4 (3.1, 9.6) <0.001 9.5 (5.3, 16.8) <0.001 26.6 (15.5, 45.7) <0.001
≥3 metabolic  
features
2.6 (1.0, 6.6) 0.043 5.4 (2.4, 12.0) <0.001 7.8 (3.5, 17.5) <0.001 22.2 (10.5, 47.0) <0.001
Pre-diabetes 0.6 (0.2, 1.4) 0.227 1.6 (0.9, 3.1) 0.142 1.6 (0.8, 3.2) 0.218 3.4 (1.9, 6.0) <0.001
High C3 1.3 (0.8, 2.1) 0.260 2.8 (1.9, 4.3) <0.001 3.3 (2.1, 5.0) <0.001 7.9 (5.4, 11.6) <0.001
High CRP 1.6 (1.0, 2.6) 0.032 1.8 (1.2, 2.7) 0.007 3.6 (2.4, 5.5) <0.001 6.1 (4.2, 8.9) <0.001
High IL-6 1.0 (0.7, 1.6) 0.897 1.1 (0.8, 1.7) 0.541 1.7 (1.2, 2.6) 0.008 2.7 (1.9, 3.8) <0.001
High TNF-α 1.1 (0.7, 1.6) 0.738 1.4 (1.0, 2.0) 0.089 1.2 (0.8, 1.9) 0.323 2.2 (1.5, 3.1) <0.001
Low adiponectin 1.4 (0.8, 2.3) 0.204 2.7 (1.8, 4.2) <0.001 2.6 (1.6, 4.2) <0.001 3.9 (2.6, 6.0) <0.001
High leptin 3.6 (2.1, 6.3) <0.001 5.9 (3.5, 9.9) <0.001 15.7 (9.3, 26.6) <0.001 46.6 (27.9, 77.6) <0.001
High resistin 1.3 (0.9, 1.9) 0.205 1.3 (0.9, 1.9) 0.194 1.5 (1.0, 2.2) 0.046 1.8 (1.2, 2.5) 0.001
High PAI-1 1.2 (0.8, 1.8) 0.460 2.0 (1.3, 2.9) <0.001 1.9 (1.3, 2.9) 0.002 2.7 (1.9, 3.9) <0.001
High WBC 1.5 (1.0, 2.4) 0.073 1.9 (1.2, 2.9) 0.003 2.7 (1.7, 4.2) <0.001 3.2 (2.2, 4.8) <0.001
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lifestyle behaviours and inclusion of a wide range of met-
abolic variables to define cardiometabolic health. Our 
findings are of potential public health and clinical signifi-
cance in terms of screening and the use of stratification 
based on obesity assessment as a method for determining 
cardiometabolic risk.
Notwithstanding these strengths, methodological limi-
tations should be considered when examining results 
from this study. Given the modest number of outcomes 
within our sample, we did not stratify by gender in analy-
sis. Although some studies have implied heterogeneous 
relationships between measures of adiposity and car-
diometabolic outcomes relating to gender [11], previ-
ous work by our group has suggested that these may be 
explained by sex differences in obesity prevalence [30]. 
In addition, recommended risk cut-points for BMI and 
WHtR are the same for men and women, and the gender 
variable was accounted for in statistical analyses.
Also of concern is that we did not use established obe-
sity index cut-offs and that our data were cross-sectional, 
as this precludes examination of temporal relationships. 
Although World Health Organisation cut-points for BMI 
are commonly used [5], and thresholds for WHtR have 
been recommended [14, 37], for the purposes of this 
research it was necessary to place both variables on the 
same scale. Future studies, utilising longitudinal data, will 
be needed to evaluate the applicability, validity and reli-
ability of joint measurement [14] using established and 
recommended diagnostic cut-points. In particular, it will 
be necessary to determine whether risk stratification, 
using both BMI and WHtR, is clinically useful and supe-
rior to currently recommended BMI classification [38].
Finally, our data were derived from a single primary 
care based sample which may not be representative of the 
source population. However, Ireland presents a generally 
ethnically homogeneous group [39]. Thus, the relation-
ships we observed are likely to be similar in other mid-
dle-aged Irish adults. In addition, random sampling of 
subjects and the use of validated methods for data collec-
tion ensured internal sample validity and the results from 
this research may be generalisable to a similar middle-
aged Caucasian-European population.
Table 4 Area under the receiver operating characteristic curve values (95 % CI) for index models to discriminate cardio-
metabolic risk features
All models include age and gender
a 5-category variable: 1 normal weight by both, 2 overweight by either, 3 overweight by both, 4 obese by either and 5 obese by both. Overweight subjects classified 
as obese by either index were assigned to the higher category
b P < 0.05 compared to BMI (continuous)
c P < 0.05 compared to WHtR (continuous)
d P < 0.05 compared to BMI (categorical)
e P < 0.05 compared to WHtR (categorical)
Feature As a continuous variable As a categorical variable (tertiles) Overweight 
and obese 
by either or bothaBMI alone WHtR alone Both BMI  
and WHtR
BMI alone WHtR alone
AUC 95 % CI AUC 95 % CI AUC 95 % CI AUC 95 % CI AUC 95 % CI AUC 95 % CI
High triglycerides 0.68 0.65, 0.71 0.71b 0.68, 0.73 0.71b 0.68, 0.74 0.68 0.65, 0.71 0.70d 0.67, 0.73 0.70d 0.67, 0.73
Low HDL-C 0.67 0.63, 0.70 0.68 0.65, 0.72 0.68 0.65, 0.71 0.66 0.62, 0.69 0.67 0.64, 0.71 0.68d 0.64, 0.71
Dyslipidaemia 0.68 0.64, 0.73 0.70 0.65, 0.74 0.70 0.65, 0.74 0.69 0.64, 0.73 0.69 0.65, 0.73 0.70 0.66, 0.74
High BP 0.70 0.67, 0.72 0.70 0.67, 0.72 0.70 0.68, 0.72 0.69 0.67, 0.72 0.69 0.67, 0.71 0.70 0.67, 0.72
Insulin resistance 0.80 0.78, 0.82 0.80 0.78, 0.83 0.81b,c 0.79, 0.83 0.78 0.76, 0.80 0.77 0.75, 0.80 0.79d,e 0.77, 0.82
≥3 metabolic features 0.76 0.73, 0.79 0.78b 0.75, 0.81 0.78b 0.75, 0.81 0.75 0.72, 0.78 0.75 0.72, 0.78 0.77d,e 0.74, 0.80
Pre-diabetes 0.70 0.66, 0.74 0.70 0.66, 0.74 0.70 0.66, 0.74 0.67 0.63, 0.71 0.68 0.64, 0.72 0.69d 0.65, 0.73
High C3 0.70 0.67, 0.73 0.72b 0.69, 0.75 0.72b 0.69, 0.75 0.69 0.66, 0.71 0.70 0.67, 0.73 0.71d 0.68, 0.73
High CRP 0.69 0.66, 0.72 0.69 0.67, 0.72 0.70b 0.67, 0.72 0.67 0.64, 0.70 0.68 0.65, 0.71 0.69d 0.66, 0.72
High IL-6 0.66 0.63, 0.69 0.67 0.64, 0.69 0.67 0.64, 0.69 0.65 0.62, 0.68 0.66 0.63, 0.69 0.66d 0.63, 0.69
High TNF-α 0.63 0.60, 0.66 0.63 0.60, 0.66 0.63 0.60, 0.66 0.62 0.59, 0.65 0.63 0.61, 0.66 0.63d 0.60, 0.66
Low adiponectin 0.79 0.77, 0.81 0.79 0.77, 0.81 0.79 0.77, 0.81 0.79 0.77, 0.81 0.79 0.76, 0.81 0.79 0.77, 0.81
High leptin 0.86c 0.84, 0.87 0.84 0.82, 0.86 0.86c 0.84, 0.88 0.84e 0.82, 0.86 0.81 0.79, 0.83 0.84e 0.82, 0.86
High resistin 0.57 0.54, 0.60 0.56 0.53, 0.59 0.57 0.54, 0.60 0.57 0.54, 0.60 0.56 0.53, 0.59 0.56 0.53, 0.60
High PAI-1 0.61 0.58, 0.64 0.62 0.59, 0.65 0.62 0.59, 0.65 0.62 0.59, 0.64 0.62 0.59, 0.65 0.62 0.59, 0.65
High WBC 0.59 0.56, 0.62 0.61b 0.58, 0.64 0.63b,c 0.60, 0.66 0.58 0.55, 0.61 0.60d 0.57, 0.63 0.59d 0.56, 0.62
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Conclusions
In summary, our findings reveal that cardiometabolic risk 
profiles in individuals defined as overweight or obese, by 
both BMI and WHtR, are significantly increased when 
compared to subjects categorised by either index sepa-
rately. Use of both measures also improved discrimination 
of individual cardiometabolic risk factors and identified a 
subset of at-risk individuals who might otherwise be missed. 
Although assessment of WC, in addition to BMI, competes 
for the limited time available during patient appraisal within 
clinical practice [9], obtaining two measurements (one for 
general obesity, and one for central obesity) does not entail 
any extra cost [14]. In light of the increasing prevalence of 
cardiometabolic diseases worldwide [40], effective methods 
that help to identify subjects at greatest risk are needed. Risk 
stratification utilising BMI and WHtR together may provide 
a simple, cost-effective and more accurate technique for 
predicting obesity-related cardiometabolic events. Earlier 
identification of individuals at risk could enable earlier tar-
geted interventions or therapies, thus attenuating develop-
ment of cardiovascular complications.
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